Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
Pallis AG, Polyzos A, Boukovinas I, Agelidou A, Lamvakas L, Tsiafaki X, Agelidou M, Pavlakou G, Chandrinos V, Kakolyris S, Christophyllakis C, Kentepozidis N, Giassas S, Androulakis N, Agelaki S, Georgoulias V. Pallis AG, et al. Among authors: agelaki s. J Thorac Oncol. 2008 May;3(5):505-10. doi: 10.1097/JTO.0b013e31816b4b32. J Thorac Oncol. 2008. PMID: 18449003 Free article.
Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
Baka S, Agelaki S, Kotsakis A, Veslemes M, Papakotoulas P, Agelidou M, Agelidou A, Tsaroucha E, Pavlakou G, Gerogianni A, Androulakis N, Vamvakas L, Kalbakis K, Mavroudis D, Georgoulias V. Baka S, et al. Among authors: agelaki s. Anticancer Res. 2010 Jul;30(7):3031-8. Anticancer Res. 2010. PMID: 20683051 Clinical Trial.
A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer.
Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N, Pavlakou G, Kotsakis A, Kontopodis E, Georgoulias V. Pallis AG, et al. Among authors: agelaki s. BMC Cancer. 2010 Nov 19;10:633. doi: 10.1186/1471-2407-10-633. BMC Cancer. 2010. PMID: 21092076 Free PMC article. Clinical Trial.
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Pallis AG, Syrigos K, Kotsakis A, Karachaliou N, Polyzos A, Chandrinos V, Varthalitis I, Christophyllakis C, Ardavanis A, Vamvakas L, Vardakis N, Saridaki Z, Samonis G, Giassas S, Georgoulias V, Agelaki S. Pallis AG, et al. Among authors: agelaki s. Clin Lung Cancer. 2011 Mar;12(2):100-5. doi: 10.1016/j.cllc.2011.03.004. Epub 2011 Apr 11. Clin Lung Cancer. 2011. PMID: 21550556 Clinical Trial.
Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V; Breast Cancer Committee of the Hellenic Oncology Research Group. Ardavanis A, et al. Among authors: agelaki s. Cancer Chemother Pharmacol. 2006 Dec;58(6):742-8. doi: 10.1007/s00280-006-0236-3. Epub 2006 May 23. Cancer Chemother Pharmacol. 2006. PMID: 16718470 Clinical Trial.
A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V. Kotsakis A, et al. Among authors: agelaki s. Cancer Chemother Pharmacol. 2011 Aug;68(2):415-22. doi: 10.1007/s00280-010-1508-5. Epub 2010 Nov 11. Cancer Chemother Pharmacol. 2011. PMID: 21069335 Clinical Trial.
168 results